Phase 3 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Grifols Therapeutics LLC40 enrolled2 locationsNCT07540221
Recruiting
Phase 3
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Chronic Inflammatory Demyelinating PolyradiculoneuropathyPolyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi140 enrolled124 locationsNCT06290128
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Chronic Inflammatory Demyelinating PolyneuropathyChronic Inflammatory Demyelinating PolyradiculoneuropathyCIDP
argenx160 enrolled19 locationsNCT07091630
Recruiting
Phase 3
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda59 enrolled52 locationsNCT06747351